CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 47 enrolled
Drug / intervention
Tirzepatide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04004988
NCT04004988Phase 1Completed
CompareCT.gov

A Study to Compare the Pharmacokinetics of Tirzepatide Administered Subcutaneously by an Autoinjector Versus Prefilled Syringe in Healthy Subjects

Eli Lilly and Company·interventional·Posted Jul 2, 2019·Updated Apr 18, 2023

In Brief

A Phase 1 clinical trial evaluating Tirzepatide, Prefilled syringe (PFS), and 1 other intervention for Healthy. Completed, enrolled 47 participants across 1 site.

Detailed Summary

The purpose of this study is to compare the amount of tirzepatide that gets into the blood stream and how long it takes the body to get rid of it, when given as a solution formulation via an autoinjector versus a conventional prefilled syringe. The tolerability of tirzepatide will also be evaluated and information about any adverse effects experienced will be collected. Screening is required within 28 days prior to the start of the study. For each participant, the total duration of the clinical trial will be about 14 weeks, including screening.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesSingapore
Collaborators--

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedJul 2, 2019
Enrollment StartAug 19, 2019
Primary CompletionDec 16, 2019
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 7 years ago

Interventions

Tirzepatidedrug

Administered SC

Prefilled syringe (PFS)device

PFS used to administer tirzepatide

Auto-injector (AI)device

AI used to administer tirzepatide